SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
----------
<TABLE>
<CAPTION>
<S> <C>
Date of Report (Date of earliest event reported) January 28, 2000 Commission File Number 0-23155
</TABLE>
TRIMERIS, INC.
(Exact name of registrant)
Delaware 56-1808663
(State of organization) (I.R.S. Employer Identification Number)
4727 University Drive, Suite 100, Durham, North Carolina 27707
(Address of principal executive offices and zip code)
(919) 419-6050
(Registrant's telephone Number)
<PAGE>
ITEM 5. OTHER EVENTS
Trimeris, Inc. incorporates herein by reference the information
contained in the press release filed as Exhibit 99 to this Current Report.
ITEM 7. EXHIBITS
EXHIBIT NO.
99 Press Release by Trimeris, Inc., dated January 28, 2000
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
TRIMERIS, INC.
By: /s/ Dani P. Bolognesi
----------------------------------------------------
Dani P. Bolognesi
Chief Executive Officer and Chief Scientific Officer
Dated: January 28, 2000
EXHIBIT NO. 99
[LOGO] TRIMERIS
FOR IMMEDIATE RELEASE
Contact: Amy Martini
Noonan/Russo Communications, Inc.
Phone: (212) 696-4455 ext. 255
Contact: Trimeris, Inc.
Phone: (919) 419-6050
TRIMERIS RAISES APPROXIMATELY $65 MILLION THROUGH PRIVATE PLACEMENT
DURHAM, NC, JANUARY 28, 2000 -- Trimeris, Inc. (Nasdaq: TRMS) today announced
that it has offered and intends to complete a private placement of Trimeris'
common stock to new and current shareholders in order to raise net proceeds of
up to approximately $65 million.
In connection with this private placement, the company intends to issue up to
1.75 million shares of common stock. Net proceeds from the private placement
will be used to fund the clinical development of its product candidates, T-20
and T-1249, to fund increased research and development, to provide working
capital and for general corporate purposes.
The securities sold in this private placement have not been registered under the
Securities Act of 1933 and may not be offered or sold in the United States in
the absence of an effective registration statement or exemption from
registration requirements. The company expects to file a registration statement
on Form S-3 within 30 days after the closing of the transaction for purposes of
registering the resale of the shares of common stock issued in the private
placement.
ABOUT TRIMERIS, INC.
Trimeris is a development stage, biopharmaceutical company engaged in the
discovery and development of novel therapeutic agents that block viral infection
by inhibiting viral fusion with host cells. Trimeris' lead product candidate,
T-20, which inhibits fusion of the human immunodeficiency virus (HIV) with host
cells, is currently in Phase II clinical trials and has received fast-track
designation from the FDA. Trimeris' second fusion inhibitor product candidate,
T-1249, which also inhibits HIV fusion, has received fast-track designation from
the FDA and is in Phase I clinical testing.
For more information on Trimeris, Inc., visit the company's web site at
www.trimeris.com.
-more-
<PAGE>
-2-
TRIMERIS SAFE HARBOR STATEMENT
Note: Except for any historical information presented herein, matters presented
in this release are forward-looking statements that involve risks and
uncertainties. The results of Trimeris' previous clinical trials are not
necessarily indicative of future clinical trials, and future results could
differ materially from the results presented herein. Factors that could cause or
contribute to such differences include, but are not limited to, those discussed
in the "Risk Factors" section included in Trimeris' Form 10-Q for the three
months ended March 31, 1999, filed with the Securities and Exchange Commission
on May 17, 1999, and the Company's Registration Statement on Form S-3 as
declared effective by the Securities and Exchange Commission on May 26, 1999.
# # #
